Earnings Alerts

Imeik Technology Development C (300896) Q3 Earnings Reveal 464.6M Yuan Net Income with Strong Revenue Growth

By October 23, 2024 No Comments
  • Imeik Technology’s net income for the third quarter is 464.6 million yuan.
  • The company reported a revenue of 718.6 million yuan for the same period.
  • Analyst recommendations include 34 buys, 2 holds, and 0 sells, showing strong market confidence in the company’s performance.

A look at Imeik Technology Development C Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth5
Resilience5
Momentum5
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Imeik Technology Development C, known for manufacturing and distributing biomedical products like sodium hyaluronate and medical devices, has garnered positive Smartkarma Smart Scores in various aspects. With impressive scores in Growth, Resilience, and Momentum, the company seems to be positioned well for long-term success. A high Growth score indicates potential for expanding operations and increasing market share, while Resilience and Momentum scores suggest the company’s ability to adapt to challenges and maintain a strong performance trend.

Although Imeik Technology Development C scored lower in Value and Dividend factors, the strong performance in Growth, Resilience, and Momentum signifies a promising outlook for the company’s future. Investors may find the company attractive based on its growth potential, resilience in adverse conditions, and positive momentum in the market.

### Summary ###
Imeik Technology Development Co., Ltd. manufactures and distributes biomedical products such as sodium hyaluronate, collagens, polylactic acids, and medical devices.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars